Bharat Biotech, Alopexx partner to develop new broad-spectrum vaccine

Bharat Biotech has announced a new partnership with US-based clinical-stage biotech player Alopexx to co-develop and commercialise AV0328, an antimicrobial vaccine designed to fight a wide range of infections. This alliance aims to enhance global access to AV0328, particularly targeting low-income and lower-middle-income countries.

As part of the agreement, Alopexx will receive an upfront payment, milestone payments, and royalties from future sales in the licensed territories. Bharat Biotech, known for its expertise in vaccine development and manufacturing, will lead the vaccine’s development and commercialisation in India and other specified regions.

Speaking on the significance of this vaccine, Sabine Kapasi, advisor, public health and healthcare services strategist, United Nations Nations Nations COVID-19 Task Force, stated, "This vaccine represents a crucial advancement in our fight against antimicrobial resistance. While it may not seem groundbreaking on its own, the shift towards preventive measures for bacterial infections, rather than relying solely on treatments, is a necessary step forward.”